[Expression and prognostic value of CARD11 in diffuse large B cell lymphoma]

Area of Science:

• Hematology
• Oncology
• Molecular Biology

Background:

• Diffuse large B cell lymphoma (DLBCL) is an aggressive non-Hodgkin lymphoma.
• Identifying novel prognostic markers is crucial for risk stratification and treatment decisions in DLBCL.
• CARD11 (caspase recruitment domain-containing protein 11) is a key signaling molecule in lymphocytes.

Purpose of the Study:

• To investigate the expression levels of CARD11 in DLBCL.
• To evaluate the prognostic significance of CARD11 expression in DLBCL patients.

Main Methods:

• Retrospective analysis of 79 previously untreated DLBCL patients.
• Immunohistochemical analysis of CARD11 expression on tissue microarrays.
• Correlation of CARD11 expression with clinical characteristics and patient outcomes (event-free survival, EFS).

Main Results:

• High CARD11 expression was observed in 65.33% of DLBCL cases.
• High CARD11 expression was significantly associated with inferior event-free survival (2-year EFS: 52.03% vs 86.12%, P=0.036).
• This association remained significant even in patients with a high International Prognostic Index (IPI) score (3-5 points).

Conclusions:

• Elevated CARD11 expression is linked to poorer outcomes in DLBCL patients.
• CARD11 may serve as a valuable biomarker for stratifying high-risk DLBCL patients.
• Further research into CARD11's role could refine prognostic models and therapeutic strategies for DLBCL.